CClinicalTrials.gg
RecruitingNCT06000085Updated Sep 13, 2023

Clinical Performance of Two Different Restorative Materials in Restoring Class II Cavities of Primary Molars

An interventional study of restoration of proximal cavities of primary molars with flowable giomer and restoration of proximal cavities of primary molars with highly viscous glass ionomer cement in Dental Caries Class II, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 4 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Dec 2022, registered Aug 2023).
  • Started Dec 2022; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
4 Years to 8 Years
Sex
All
01

Study summary

The aim of the present study is to assess Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo,

Japan) in class II cavities of primary molars regarding the following objectives:

The primary objective To evaluate and compare the clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars after 3,6, and 12 months. The secondary objective To assess the effect of different independent variables on the treatment outcome of the experimental restorative materials.

Research question:

Is there a difference in the clinical performance between flowable giomers and highly viscous glass ionomer in restoring class II cavities of primary molars?

Null Hypothesis There is no difference in the clinical performance between Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) after one year of follow up.

Read the detailed description

Study design:

The study will be two parallel-arm, double blinded randomized, controlled clinical trial with an equal allocation ratio.

Study Setting:

The study will be conducted at Pediatric dentistry and Dental Public Health Department, Faculty of Dentistry, Ain Shams University.

Ethical Considerations:

  • The study methodology will be reviewed and approved by the faculty research ethical committee.
  • Guardians of children will be asked to sign an informed consent in simple Arabic language before being enrolled in this study. The parents will be assured about confidentiality of all the collected data and were informed that their child has the right to withdraw at any given point during treatment without having to provide reasons for withdrawal.
  • Children also will fill a simplified assent form.

Sample Size:

Sample size estimation was based on testing the null hypothesis that there is no difference between the clinical success rates of the two materials by setting α error of 5%, power of 80%, and allocation ratio 1:1. Results from previous studies suggested that the one-year clinical success rate of EQUIA Forte™ in class II restorations in primary molars was 74.4% (24) , while that for Beautifil flow plus x was estimated to be 94.1% based upon the findings of a previous study regarding Giomer in class II cavities. Based on this, the needed sample is 53 primary molars per group. Considering 15% drop-out rate, the needed sample size was increased to 62 molars per group. Sample size calculation was performed using G*Power software version 3.1.9.4 for MS Windows Study Population A total of 124 primary molars fulfilling the eligibility criteria will be restored in eligible participants, with one of the two tested restorative materials.

Study grouping:

The study will include two groups:

Group I (experimental): 62 primary molars will be restored with flowable Giomer beautifil flow plus x Group II (comparator): 62 primary molars will be restored with high-viscosity glass ionomer cement (EQUIA Forte)

Randomization and blinding:

Randomization will be performed using the Computer generated random number table to ensure that each primary molar had an equal chance of being assigned to either the glass ionomer group or the giomer group. Randomization will be done by tooth such that participants with multiple eligible carious primary molars were allowed to draw a corresponding number of cards. This trial will be double-blinded such that all participants, the clinical evaluator and the data analyst will be blinded to the type of the applied restorative materials in all periods of the study.

Allocation concealment:

The randomization groups will be written on a paper and each of the papers will be numbered and will be individually packed by another person than the investigator in an opaque envelope after folding each paper eight folds. All participants will be asked to select an opaque sealed envelope for each of their carious primary molars to avoid allocation bias. The numbers in the envelopes determined the group assigned for each molar. The investigator will open the sealed envelope after the cavity preparation and then assigns the treatment group accordingly.

Implementation:

A. Sequence generation will be done by a trial independent subject. B. Recruitment and screening of participants will be done by the main investigator, while enrolling of primary molars for the trial will be decided by two calibrated dentists.

Participants and assessors will be blinded at baseline and follow up. The primary investigator will not be blinded. C. Envelops will be kept with a trial independent subject and the allocated treatment will be revealed after cavity preparation

Study population:

Patients attending the Department of Pediatric Dentistry and dental public health, Faculty of Dentistry, at Ain Shams University for routine dental care will be examined clinically and radiographically with bite-wing radiography. Patients will be assessed for eligibility for participation.

Study Procedure

A detailed case history will be recorded, and an oral examination will be done. Oral prophylaxis will be performed to all the study children before the restorative treatment. A total of 124 primary molars (first/second, maxillary/mandibular) with carious lesions that indicated for restorative treatment will be selected by specified inclusion criteria. Based on the type of restorative material, the teeth will be randomly allocated to two groups (n = 62 in each group) Initial bite-wing radiographs of the teeth to be treated will be taken before the treatment.

Local anesthesia will be applied. Cavity preparations will be performed using diamond burs at high speed with water-cooling. Hand instruments and slow-speed tungsten carbide burs were used to remove the caries. Conservative cavity design will be used and beveling will not applied to the cavity walls to avoid unnecessary loss of hard dental tissue. The outline shape of the cavity will be limited to the removal of caries lesion. Any additional retention will not be prepared. The cavity will be rinsed and then dried with cotton pellets. A metal matrix band and wedges will be applied. Cotton rolls and a saliva ejector will be used for isolation.

Group 1 Giomer; Beautifil flow plus x After caries tissue removal, the cavity will be washed by rubbing wet cotton pellets against its walls to remove debris and remnants of decayed tissue removal. In the presence of the adjacent tooth, a matrix band and a wooden wedge were placed to adapt the restoration. A thin layer of the one-step self-etch adhesive BeautiBond (Shofu Inc) will be applied with a micro applicator and light cured for 10 s. The operator will place the Beautifil-flow plus x in increments creating the desired shape. Each increment will be light-cured for 20 s at each restoration surface. The composite will be used in increments up to 2 mm. An articulation paper will be used to check if there is any interference.

Group 2 Glass-hybrid-added HVGIC; Equia Forte:

The cavity will be conditioned with a poly- acrylic acid 'dentin conditioner' (EQUIA GC, JAPAN) which will be left for 15 seconds according to the manufacturer instructions. The conditioner will later be washed with a water spray, and then rinsing water will be blotted with a dry cotton pellet, leaving a moist surface. Each capsule of high viscous glass ionomer cement will be mixed for 10 seconds using amalgamator according to the manufacturer's instructions then packed into the prepared cavity with a carver and ball burnisher. Any excess material will be removed using a carver. Finally, a thin layer of the Equia Forte Coat ® (GC Corp) will be applied with a micro applicator and then light-cured for 20 s. An articulation paper will be used to check if the restoration caused any occlusal interference.

02

Conditions studied

  • Dental Caries Class II

Browse trials for

Keywords

  • proximal caries
  • primary molars
  • flowable giomer
  • equia forte
03

In context

Dental Caries

1,109 studies on the registry are indexed under Dental Caries; 197 are open to participants now.

This study's planned enrollment of 124 is above the median of 60 across 916 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

inclusion criteria of study participants:

  1. 4 to 8 years old medically free children.
  2. Cooperative children classified as class 3 or 4 based on Frankel et al. classification
  3. Children who had at least one active dentinal carious lesion on proximal surface of primary molars

inclusion criteria of teeth:

  1. Primary molars with active dentinal carious lesion on their proximal surface score 4, 5 using ICDAS.
  2. Primary molars with proximal carious lesion extended to outer and middle third of dentin scored D1and D2 that will be detected by bitewing radiograph.
  3. Simple or compound class II cavities be present
  4. The antagonist and the adjacent tooth should be present
  5. Primary molar should have at least 2/3 of the root present

Exclusion Criteria:

exclusion criteria of study participants

  1. Refusal of the parents to sign the informed consent
  2. Presence of deep bite or any pictures of malocclusion and any parafunctional habits.

exclusion criteria of teeth

  1. Presence of any unprovoked pain, pulp exposure,clinical swelling, abscess or fistula.
  2. Presence of any physiological or pathological mobility.
  3. Very deep subgingival cavities
  4. Teeth with congenitally missing successor
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Flowable Giomer Beautifil flow plus x

    injectable flowable restorative material

    Procedure: restoration of proximal cavities of primary molars with flowable giomer

  • Active comparator
    Glass-hybrid-added HVGIC Equia Forte

    Glass-hybrid-added Highly viscous glass ionomer cement

    Procedure: restoration of proximal cavities of primary molars with highly viscous glass ionomer cement

Interventions

  • Procedurerestoration of proximal cavities of primary molars with flowable giomer

    removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x

  • Procedurerestoration of proximal cavities of primary molars with highly viscous glass ionomer cement

    removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte

06

What researchers measure

Primary outcomes

  1. The clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars

    The restorations will be evaluated using the FDI criteria having esthetic, functional, and biological properties

    Time frame: 12 months

Secondary outcomes

  1. The effect of different independent variables on the treatment outcome of the experimental restorative materials.

    assessment of the effect of different variables such as the age of the patient and the properties of the tooth on the restoration survival

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Faculty of dentistry ain shams university
    Cairo, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06000085
Lead sponsor
Ain Shams University
Responsible party
Sarah Emad Ali El-Din (Assistant lecturer at the Pediatric Dentistry and Dental Public Health Department-Faculty of Dentistry, Ain Shams University) — Principal investigator
First posted
Aug 21, 2023
Start date
Dec 30, 2022
Primary completion
Jun 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Sep 13, 2023

Study contacts

Sarah Emad
Contact
dent.sarah.emad@gmail.com
01005699595
Sarah Emad
principal investigator · faculty of dentistry ain shams university

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion